Compositions of a polyorthoester and an aprotic solvent

US9913909B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9913909-B2
Application numberUS-201615269806-A
CountryUS
Kind codeB2
Filing dateSep 19, 2016
Priority dateMar 15, 2013
Publication dateMar 13, 2018
Grant dateMar 13, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of administering a therapeutically active agent to a subject in need thereof, comprising: dispensing and administering to the subject a delivery system, wherein the delivery system comprises: a polyorthoester of Formula III; where A is R 1 or R 3 , R* is C1-4 alkyl, n ranges from 5 to 1000, R 1 is: p and q are integers that vary from between about 1 to 20 and the average number of p or the average of the sum of p and q is between 1 and 7; R 3 and R 6 are each independently: x is an integer of 1-4; R 5 is H or methyl, and the fraction of A units that are of formula R 1 is between 10-25 mole percent; an aprotic solvent in which the polyorthoester is miscible to form a single phase, wherein the aprotic solvent is selected from dimethyl sulfoxide, dimethyl acetamide, and N-methyl pyrrolidone; and a local amide- or anilide-type anesthetic dispersed or solubilized in the single phase, wherein the aprotic solvent is present in amounts ranging from about 10-25% by weight of the delivery system and the polyorthoester of formula III is present in amounts ranging from about 45-80% by weight of the delivery system. 2. A method of treating pain in a subject in need thereof, comprising: dispensing and administering to the subject a composition comprised of a therapeutically effective amount of a delivery system, wherein the delivery system comprises: a polyorthoester of Formula III; where A is R 1 or R 3 , R* is C1-4 alkyl, n ranges from 5 to 1000, R 1 is: p and q are integers that vary from between about 1 to 20 and the average number of p or the average of the sum of p and q is between 1 and 7; R 3 and R 6 are each independently: x is an integer of 1-4; R 5 is H or methyl, and the fraction of A units that are of formula R 1 is between 10-25 mole percent; an aprotic solvent in which the polyorthoester is miscible to form a single phase, wherein the aprotic solvent is selected from dimethyl sulfoxide, dimethyl acetamide, and N-methyl pyrrolidone; and a local amide- or anilide-type anesthetic dispersed or solubilized in the single phase. 3. The method of claim 2 , wherein the method reduces or prevents pain in the subject. 4. The method of claim 2 , wherein the administering comprises administering the composition locally. 5. The method of claim 4 , wherein the administering comprises administering the composition intrathecally, at a nerve, into the epidural space, or to a surgical wound. 6. The method of claim 2 , wherein the administering comprises administering the composition regionally. 7. The method of claim 6 , wherein the administering comprises administering the composition as a nerve block or as a sensory block. 8. The method of claim 2 , wherein the active agent is selected from the group consisting of bupivacaine, ropivacaine, levobupivacaine, dibucaine, mepivacaine, procaine, lidocaine, and tetracaine. 9. The method of claim 2 , wherein the therapeutically active agent is bupivacaine. 10. The method of claim 2 , wherein the therapeutically active agent is ropivacaine. 11. The method of claim 2 , wherein the delivery system has a viscosity of less than about 10,000 cP at 37° C. 12. The method of claim 2 , wherein the aprotic solvent is dimethyl sulfoxide. 13. The method of claim 1 , wherein the method comprises dispensing the delivery system from a tube. 14. The method of claim 1 , wherein the method comprises administering to the subject the delivery system in an amount effective to prevent or reduce pain. 15. The method of 1 , wherein the aprotic solvent is dimethyl sulfoxide.

Assignees

Inventors

Classifications

  • Local anaesthetics · CPC title

  • Antidiarrhoeals · CPC title

  • Morphinan derivatives, e.g. morphine, codeine · CPC title

  • A61K47/34Primary

    Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

  • Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9913909B2 cover?
Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is …
Who is the assignee on this patent?
Heron Therapeutics Inc
What technology area does this patent fall under?
Primary CPC classification A61K47/34. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).